ArticleJournal of translational medicine2026
Macrophage-derived IL-6 reprograms lipid metabolism to promote colorectal cancer development through USP14-mediated FASN deubiquitination.
Article in Journal of translational medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
backgroundInflammation and metabolic reprogramming are hallmark features of tumors. However, the role of the inflammatory microenvironment in orchestrating lipid metabolic changes and the associated mechanisms remains unclear. This study investigates the impact of macrophage-derived interleukin-6 (IL-6) on lipid metabolism in colorectal cancer and explores the underlying mechanisms.
methodsMacrophage infiltration was assessed using immunofluorescence. Oil Red O, BODIPY 493/503, and lipidomics measured cellular lipid levels. ELISA quantified cytokine levels secreted by macrophages. Co-immunoprecipitation and Western blot analyzed interactions between ubiquitin-specific-processing protease 14 (USP14) and fatty acid synthase (FASN). ChIP and luciferase assays confirmed signal transducer and activator of transcription 3 (STAT3)’s effect on USP14 transcription. AutodockVina 1.2.2 and cellular thermal shift assay were used to analyze the interaction between USP14 and 6-gingerol.
resultsIn murine models, macrophage infiltration induced by dextran sodium sulfate (DSS) or lipopolysaccharides (LPS) increased lipid and FASN levels, accelerating colorectal cancer progression. Depletion of macrophages reduced LPS-induced tumor growth and lipid levels. Conditioned medium from macrophages elevated FASN expression and lipid accumulation in CRC cells, effects reversed by anti-IL-6 antibody. IL-6 significantly increased FASN expression and tumor progression in CT26 allograft mice. Mechanistically, IL-6 activated STAT3, which upregulated USP14, thereby stabilizing FASN and promoting lipogenesis. Additionally, we identified 6-gingerol as a USP14 inhibitor that suppresses FASN expression and tumor progression.
conclusionsOur findings reveal a novel signaling axis involving IL-6, STAT3, USP14, and FASN, activated by macrophage infiltration in colorectal cancer. This study underscores the critical role of IL-6 in enhancing FASN expression, providing potential therapeutic and prognostic strategies for inflammation-related cancers.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.